How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,178 results for

Mycobacterium Avium Complex

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

981. Wasting syndrome and disruption of the somatotropic axis in simian immunodeficiency virus-infected macaques with Mycobacterium avium complex infection. Full Text available with Trip Pro

Wasting syndrome and disruption of the somatotropic axis in simian immunodeficiency virus-infected macaques with Mycobacterium avium complex infection. Mycobacterium avium is a common opportunistic infection of patients with acquired immunodeficiency syndrome (AIDS). We used the simian immunodeficiency virus (SIV)-infected rhesus macaque (Macaca mulatta) model to examine whether disseminated M. avium is associated with disruption of the somatotropic axis in AIDS. Macaques were followed (...) levels (day 0 [2.00 ng/mL] vs. DOD [8.58 ng/mL]; P=.026, Mann-Whitney rank sum test). These data document alterations in the somatotropic axis secondary to experimental disseminated M. avium infection and suggest that similar changes may contribute to alterations in body composition during AIDS.

2004 Journal of Infectious Diseases

982. Normal CD16 expression and phagocytosis of Mycobacterium avium complex by monocytes from a current cohort of HIV-1-infected patients. Full Text available with Trip Pro

Normal CD16 expression and phagocytosis of Mycobacterium avium complex by monocytes from a current cohort of HIV-1-infected patients. Monocyte phenotype and function were measured in whole blood sampled from a current cohort of human immunodeficiency virus (HIV)-infected individuals attending a large, metropolitan, university-affiliated hospital. There was no significant difference in the prevalence of CD16+ monocytes or the capacity of monocytes to ingest heat-killed Mycobacterium avium (...) complex between these individuals and HIV-uninfected control subjects, regardless of viral load, current CD4+ T cell count, nadir CD4+ T cell count, or time since diagnosis of HIV infection. CD16+ monocyte prevalence was, however, elevated in patients not currently receiving antiretroviral therapy. We conclude that HIV type 1 infection in the setting of highly active antiretroviral therapy is associated with normal monocyte function and phenotype.

2006 Journal of Infectious Diseases

983. New agents active against Mycobacterium avium complex selected by molecular topology: a virtual screening method. Full Text available with Trip Pro

New agents active against Mycobacterium avium complex selected by molecular topology: a virtual screening method. In order to select new drugs and to predict their in vitro activity against Mycobacterium avium complex (MAC), new quantitative structure-activity relationship (QSAR) models were developed.The activities against MAC of 29 structurally heterogeneous drugs were examined by means of linear discriminant analysis (LDA) and multilinear regression analysis (MLRA) by using topological

2004 Journal of Antimicrobial Chemotherapy

984. Activity of picolinic acid in combination with the antiprotozoal drug quinacrine against Mycobacterium avium complex. Full Text available with Trip Pro

Activity of picolinic acid in combination with the antiprotozoal drug quinacrine against Mycobacterium avium complex. We studied the in vitro and in vivo antimicrobial activities of picolinic acid (PA) in combination with the antiprotozoal drug quinacrine against intramacrophage Mycobacterium avium complex (MAC). Quinacrine significantly potentiated the anti-MAC activity of PA, suggesting the usefulness of this combination in the clinical control of MAC infection.

2006 Antimicrobial Agents and Chemotherapy

985. Genetic diversity of the dnaJ gene in the Mycobacterium avium complex. Full Text available with Trip Pro

Genetic diversity of the dnaJ gene in the Mycobacterium avium complex. The Mycobacterium avium complex (MAC) is associated with various diseases in humans as a zoonosis. The dnaJ gene was partially sequenced in Schaefer's 28 reference strains of MAC, 14 human MAC isolates and 22 veterinary isolates. From substitutions affecting 21-32 nucleotides, all strains could be classified into 14 groups. Most nucleotide substitutions did not alter amino acid sequences. Approximately 8 % genetic diversity

2004 Journal of Medical Microbiology

986. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. (Abstract)

Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. Disseminated Mycobacterium avium complex infection eventually develops in most patients with the acquired immunodeficiency syndrome (AIDS). This infection results in substantial morbidity and reduces survival by about six months.We conducted two randomized, double-blind, multicenter trials of daily prophylactic treatment with either rifabutin (300 mg) or placebo. All the patients had AIDS (...) and CD4 cell counts < or = 200 per cubic millimeter. The primary end point was M. avium complex bacteremia as assessed monthly by blood culture. The secondary end points were signs and symptoms associated with disseminated M. avium complex infection, adverse events, hospitalization, and survival.In the first trial, M. avium complex bacteremia developed in 51 of 298 patients (17 percent) assigned to placebo and 24 of 292 patients (8 percent) assigned to rifabutin (P < 0.001). In the second trial

1993 NEJM Controlled trial quality: predicted high

987. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. (Abstract)

A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. Disseminated infection with Mycobacterium avium complex is the most common opportunistic infection in patients with advanced stages of the acquired immunodeficiency syndrome (AIDS). We studied the efficacy and safety of prophylactic treatment with clarithromycin, a macrolide antibiotic.We conducted a randomized, placebo (...) -controlled, double-blind study of clarithromycin in patients with AIDS in the United States and Europe. Entry criteria included blood cultures that were negative for M. avium complex, a Karnofsky performance score of 50 or higher, a CD4 cell count of 100 or less per cubic millimeter, and a life expectancy of at least six months.After the first interim analysis, the study was stopped. M. avium complex infection developed in 19 of the 333 patients (6 percent) assigned to clarithromycin and in 53 of the 334

1996 NEJM Controlled trial quality: predicted high

988. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group. (Abstract)

A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group. Bacteremia with the Mycobacterium avium complex is common in patients with the acquired immunodeficiency syndrome (AIDS), but the most effective treatment for this infection remains unclear.We randomly assigned 229 patients with AIDS and M (...) . avium complex bacteremia to receive either rifampin (600 mg daily), ethambutol (approximately 15 mg per kilogram of body weight daily), clofazimine (100 mg daily), and ciprofloxacin (750 mg twice daily) (the four-drug group) or rifabutin (600 mg daily), ethambutol (as above), and clarithromycin (1000 mg twice daily) (the three-drug group). In the three-drug group the dose of rifabutin was reduced by half after 125 patients were randomized, because 24 of 63 patients had uveitis.Among 187 patients who

1996 NEJM Controlled trial quality: uncertain

989. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group. (Abstract)

Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group. Azithromycin is active in treating Mycobacterium avium complex disease, but it has not been evaluated as primary prophylaxis in patients with human immunodeficiency virus (HIV) infection. Because the drug is concentrated in macrophages and has a long half-life in tissue, there is a rationale for once-weekly dosing.We compared three (...) prophylactic regimens in a multicenter, double-blind, randomized trial involving 693 HIV-infected patients with fewer than 100 CD4 cells per cubic millimeter. The patients were assigned to receive rifabutin (300 mg daily), azithromycin (1200 mg weekly), or both drugs. They were monitored monthly with blood cultures for M. avium complex.In an intention-to-treat analysis, the incidence of disseminated M. avium complex infection at one year was 15.3 percent with rifabutin, 7.6 percent with azithromycin

1996 NEJM Controlled trial quality: uncertain

990. Discontinuation of prophylaxis for Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. Terry Beirn Community Programs for Clinical Research on AIDS. Full Text available with Trip Pro

Discontinuation of prophylaxis for Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. Terry Beirn Community Programs for Clinical Research on AIDS. Several agents are effective in preventing Mycobacterium avium complex disease in patients with advanced human immunodeficiency virus (HIV) infection. However, there is uncertainty about whether prophylaxis should be continued in patients whose CD4+ cell counts have increased substantially (...) with antiviral therapy.We conducted a multicenter, double-blind, randomized trial of treatment with azithromycin (1200 mg weekly) as compared with placebo in HIV-infected patients whose CD4+ cell counts had increased from less than 50 to more than 100 per cubic millimeter in response to antiretroviral therapy. The primary end point was M. avium complex disease or bacterial pneumonia.A total of 520 patients entered the study; the median CD4+ cell count at entry was 230 per cubic millimeter. In 48 percent

2000 NEJM Controlled trial quality: predicted high

991. Successful discontinuation of therapy for disseminated Mycobacterium avium complex infection after effective antiretroviral therapy. (Abstract)

Successful discontinuation of therapy for disseminated Mycobacterium avium complex infection after effective antiretroviral therapy. Highly active antiretroviral therapy (HAART) is associated with improvement or resolution of several HIV-associated opportunistic infections. Although prophylaxis against disseminated Mycobacterium avium complex infection may be successfully discontinued after a favorable response to HAART, the 1999 guidelines from the U.S. Public Health Service/Infectious (...) Diseases Society of America recommend continuing therapy for disseminated M. avium complex infection, regardless of the response to HAART.To examine the outcome among patients with disseminated M. avium complex infection whose antimycobacterial therapy was discontinued after a favorable response to HAART.Retrospective chart review between May 2000 and May 2001.13 Canadian HIV clinics.52 HIV-infected adults (43 men; mean age, 37.3 years) in whom successful antimycobacterial therapy for disseminated M

2002 Annals of Internal Medicine

992. Mycobacterium Avium Complex (MAC)

Mycobacterium Avium Complex (MAC) Mycobacterium Avium Complex. MAI; MAC Information | Patient TOPICS Try our Symptom Checker TREATMENT RESOURCES Try our Symptom Checker PROFESSIONAL Upgrade to Patient Pro / / Search Mycobacterium Avium Complex Authored by , Reviewed by | Last edited 29 Aug 2014 | Certified by This article is for Medical Professionals Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK (...) and European Guidelines. You may find one of our more useful. In this article In This Article Mycobacterium Avium Complex In this article Synonyms: Mycobacterium avium-intracellulare, MAI There are two discrete species in the Mycobacterium avium complex (MAC): Mycobacterium avium (M. avium). Mycobacterium intracellulare (M. intracellulare). These two species are difficult to differentiate and therefore they are also referred to collectively as Mycobacterium avium-intracellulare (MAI) . Although it might

2008 Mentor

993. Clarithromycin-ciprofloxacin-amikacin for therapy of Mycobacterium avium-Mycobacterium intracellulare bacteremia in patients with AIDS. Full Text available with Trip Pro

Clarithromycin-ciprofloxacin-amikacin for therapy of Mycobacterium avium-Mycobacterium intracellulare bacteremia in patients with AIDS. A combination of clarithromycin, ciprofloxacin, and amikacin for the treatment of Mycobacterium avium-Mycobacterium intracellulare bacteremia was evaluated in 12 AIDS patients. Mycobacteremia cleared in all patients by 2 to 8 weeks of treatment, and symptoms resolved. Four patients died; all had negative blood cultures until death, and disseminated M. avium-M (...) . intracellulare complex infection was not considered the primary cause of death.

1992 Antimicrobial Agents and Chemotherapy

994. Differences in serological responses to specific glycopeptidolipid-core and common lipid antigens in patients with pulmonary disease due to Mycobacterium tuberculosis and Mycobacterium avium complex. Full Text available with Trip Pro

Differences in serological responses to specific glycopeptidolipid-core and common lipid antigens in patients with pulmonary disease due to Mycobacterium tuberculosis and Mycobacterium avium complex. Disease due to the Mycobacterium avium complex (MAC) is one of the most important opportunistic pulmonary infections. Since the clinical features of MAC pulmonary disease and tuberculosis (TB) resemble each other, and the former is often difficult to treat with chemotherapy, early differential (...) factor (trehalose 6,6'-dimycolate) (TDM-T) and (3) trehalose monomycolate from Mycobacterium bovis Bacillus Calmette-Guérin (BCG) (TMM-T), and (4) trehalose monomycolate (TMM-M) and (5) GPL-core from MAC. Anti-GPL-core IgG antibody was critical, and detected only in the primary and the secondary MAC diseases with high positivity, up to 88.4 %. However, IgG antibodies against Ac-PIM2, TDM-T and TMM-T were elevated in both TB and MAC patients. Anti-TMM-M IgG antibody was also elevated in MAC disease

2006 Journal of Medical Microbiology

995. Differential virulence of Mycobacterium avium strains isolated from HIV-infected patients with disseminated M. avium complex disease. Full Text available with Trip Pro

Differential virulence of Mycobacterium avium strains isolated from HIV-infected patients with disseminated M. avium complex disease. The role that colonization with Mycobacterium avium plays in the development of disseminated disease is unclear. In this study, we determined whether all M. avium strains isolated from the portals of M. avium infection are capable of crossing the mucosal border and causing infection. The patients in this study were enrolled in AIDS Clinical Trial Group protocol (...) 341. The patients were divided into 3 groups; 2 groups differed in their immunological and clinical risk for M. avium disease. A third group (n=22 patients) had culture-documented disseminated M. avium complex disease at the time of entry in the study. Eight of 22 patients had M. avium isolated from both a colonized site and blood or bone marrow specimens. All 8 patients had distinct M. avium strains; 2 patients had a polyclonal infection. The virulence properties of 13 strains were determined

2004 Journal of Infectious Diseases

996. Use of the INNO-LiPA-MYCOBACTERIA Assay (Version 2) for Identification of Mycobacterium avium-Mycobacterium intracellulare-Mycobacterium scrofulaceum Complex Isolates Full Text available with Trip Pro

Use of the INNO-LiPA-MYCOBACTERIA Assay (Version 2) for Identification of Mycobacterium avium-Mycobacterium intracellulare-Mycobacterium scrofulaceum Complex Isolates Using INNO-LiPA-MYCOBACTERIA (Lipav1; Innogenetics) and the AccuProbe (Gen-Probe Inc./bioMérieux) techniques, 35 Mycobacterium avium-Mycobacterium intracellulare-Mycobacterium scrofulaceum (MAC/MAIS) complex strains were identified between January 2000 and December 2002. Thirty-four of 35 isolates were positive only for the MAIS (...) complex probe by Lipav1 and were further analyzed by INNO-LiPA-MYCOBACTERIA version 2 (Lipav2), hsp65 PCR restriction pattern analysis (PRA), and ribosomal internal transcribed spacer (ITS), hsp65, and 16S rRNA sequences. Lipav2 identified 14 of 34 strains at the species level, including 11 isolates positive for the newly specific MAC sequevar Mac-A probe (MIN-2 probe). Ten of these 11 isolates corresponded to sequevar Mac-A, which was recently defined as Mycobacterium chimerae sp. nov. Among the last

2005 Journal of clinical microbiology

997. Clarithromycin prophylaxis against disseminated Mycobacterium avium complex in patients with AIDS. (Abstract)

Clarithromycin prophylaxis against disseminated Mycobacterium avium complex in patients with AIDS. 11362747 1995 10 24 2016 11 23 1081-454X 1 7 1995 Aug Journal of the International Association of Physicians in AIDS Care J Int Assoc Physicians AIDS Care Clarithromycin prophylaxis against disseminated Mycobacterium avium complex in patients with AIDS. 20-2 Archange Y R YR Mount Vernon Hospital, Mount Vernon, NY. Carrey Z Z Zanlungo P G PG eng Clinical Trial Journal Article Newspaper Article (...) Randomized Controlled Trial United States J Int Assoc Physicians AIDS Care 9508185 1081-454X 0 Anti-Bacterial Agents 0 Antiviral Agents H1250JIK0A Clarithromycin X Acquired Immunodeficiency Syndrome complications drug therapy Anti-Bacterial Agents pharmacology therapeutic use Antiviral Agents therapeutic use CD4 Lymphocyte Count Clarithromycin pharmacology therapeutic use Drug Therapy, Combination Humans Microbial Sensitivity Tests Mycobacterium avium Complex drug effects Mycobacterium avium

1995 Journal of the International Association of Physicians in AIDS Care Controlled trial quality: uncertain

998. [Roxithromycin therapy of patients with mycobacterium avium complex lung infection]. (Abstract)

[Roxithromycin therapy of patients with mycobacterium avium complex lung infection]. 11436830 2001 07 19 2016 11 16 0368-2781 54 Suppl A 2001 Feb The Japanese journal of antibiotics Jpn J Antibiot [Roxithromycin therapy of patients with mycobacterium avium complex lung infection]. 13-5 Matsuda H H Sennda K K Suda T T Kuwata H H Suzuki K K Yokomura K K Asada K K Nakamura Y Y Inui N N Tsuchiya T T Nakamura H H jpn Clinical Trial Comparative Study Journal Article Randomized Controlled Trial Japan (...) Jpn J Antibiot 0154402 0368-2781 0 Anti-Bacterial Agents 21KOF230FA Roxithromycin 8G167061QZ Ethambutol H1250JIK0A Clarithromycin VJT6J7R4TR Rifampin IM Aged Aged, 80 and over Anti-Bacterial Agents therapeutic use Clarithromycin therapeutic use Drug Therapy, Combination Ethambutol therapeutic use Female Humans Male Middle Aged Mycobacterium avium-intracellulare Infection drug therapy Rifampin therapeutic use Roxithromycin therapeutic use Treatment Outcome Tuberculosis, Pulmonary drug therapy 2001

2001 The Japanese journal of antibiotics Controlled trial quality: uncertain

999. A Randomized, Double-Blinded, Placebo-Controlled, Phase II Inhaled Interferon Gamma-1b and Antimycobacterials to Treat Pulmonary Mycobacterium Avium Complex Infections

A Randomized, Double-Blinded, Placebo-Controlled, Phase II Inhaled Interferon Gamma-1b and Antimycobacterials to Treat Pulmonary Mycobacterium Avium Complex Infections A Randomized, Double-Blinded, Placebo-Controlled, Phase II Inhaled Interferon Gamma-1b and Antimycobacterials to Treat Pulmonary Mycobacterium Avium Complex Infections - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search (...) for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Randomized, Double-Blinded, Placebo-Controlled, Phase II Inhaled Interferon Gamma-1b and Antimycobacterials to Treat Pulmonary Mycobacterium Avium Complex Infections The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been

2001 Clinical Trials

1000. Phase II Study of Amithiozone (Thiacetazone) for Patients With Mycobacterium Avium Complex Pulmonary Disease

Phase II Study of Amithiozone (Thiacetazone) for Patients With Mycobacterium Avium Complex Pulmonary Disease Phase II Study of Amithiozone (Thiacetazone) for Patients With Mycobacterium Avium Complex Pulmonary Disease - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. Phase II Study of Amithiozone (Thiacetazone) for Patients With Mycobacterium Avium Complex Pulmonary Disease The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00004689 Recruitment Status : Completed First Posted : February 25, 2000 Last

2000 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>